About: Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - achieving global consensus and visibility for cellular host-directed therapies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - achieving global consensus and visibility for cellular host-directed therapies Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - achieving global consensus and visibility for cellular host-directed therapies
Creator	Ippolito, Giuseppe Zumla, Alimuddin Maeurer, Markus Azhar, Esam Agrati, Chiara Wang, Fu-Sheng El-Kafrawy, Sherif Locatelli, Franco Petrosillo, Nicola Zitvogel, Laurence Mcauley, Danny Osman, Mohamed Alimuddin, Prof Gorman, Ellen O'kane, Cecilia
Source	Elsevier; Medline; PMC
abstract	Abstract As of May 11th 2020, the coronavirus disease 2019 (COVID-19) pandemic, caused by the novel, the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused 274,361 deaths out of 3,917,366 (7% case fatality rate). As with the two other novel coronavirus zoonotic diseases of humans, SARS and MERS, no specific treatments for reducing mortality or morbidity are yet available. Deaths from COVID-19 will continue to rise globally until effective and appropriate treatments and vaccines are found. With no specific treatments being available for treating COVID-19 patients, the global medical, scientific, pharma and funding communities have rapidly initiated over 500 COVID-19 clinical on a range of antiviral drug regimens, biologics, repurposed drugs in various combinations. We focus this editorial specifically on the background to, and the rationale for, the use and evaluation of mesenchymal stromal (Stem) cells (MSCs) in treatment trials of patients with severe COVID-19 disease. This is an area which has been eclipsed by the current emphasis the huge number of trials evaluating new anti-viral drugs, repurposed drugs and combinations thereof. MSCs should also be trialed for treatment of severe cases of MERS where mortality rates are upto 34% and MERS-CoV remains a WHO priority Blueprint pathogen. It’s about time funding agencies now invest more into development MSCs per se and other host-directed therapies in combination with other therapeutic interventions. MSC therapy could turn out to be an important contribution to bringing an end to the high COVID-19 and MERS death rates.
has issue date	2020-05-17(xsd:dateTime)
bibo:doi	10.1016/j.ijid.2020.05.040
bibo:pmid	32425638
has license	els-covid
sha1sum (hex)	ae5b89fc05bca331782962e71cebbf7898ac1ad7
schema:url	https://doi.org/10.1016/j.ijid.2020.05.040
resource representing a document's title	Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - achieving global consensus and visibility for cellular host-directed therapies
has PubMed Central identifier	PMC7231497
has PubMed identifier	32425638
schema:publication	Int J Infect Dis
resource representing a document's body	covid:ae5b89fc05bca331782962e71cebbf7898ac1ad7#body_text
is schema:about of	named entity 'ongoing' named entity 'COVID-19' named entity 'patients' named entity 'morbidity' named entity 'therapy' named entity 'Reducing' covid:arg/ae5b89fc05bca331782962e71cebbf7898ac1ad7 named entity 'Displays' named entity 'mortality' named entity 'host-directed therapies' named entity 'COVID-19 disease' named entity 'COVID-19' named entity 'immune mechanisms' named entity 'blood vessels' named entity 'IL-1β' named entity 'MERS' named entity 'chemokines' named entity 'hyperinflammation' named entity 'therapeutic interventions' named entity 'parenchymal cells' named entity 'biologics' named entity 'anti-viral drugs' named entity 'ACE2' named entity 'eosinophils' named entity 'pathology' named entity 'protein' named entity 'clinical trials' named entity 'alveolar epithelium' named entity 'therapeutic interventions' named entity 'coronavirus' named entity 'FDA' named entity 'ClinicalTrials.gov' named entity 'case fatality rate' named entity 'repurposed drugs' named entity 'pathogen' named entity 'host response' named entity 'pro-inflammatory cytokines' named entity 'angiotensin converting enzyme 2' named entity 'Clinical Trial' named entity 'alveolar type II cells' named entity 'phase 1' named entity 'coronaviruses' named entity 'pathogenesis' named entity 'nutritional supplements' named entity 'COVID' named entity 'marketing approval' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'macrophages' named entity 'inflammation' named entity 'COVID' named entity 'IL-10' named entity 'CD4-positive T cells' named entity 'lung' named entity 'hyaline' named entity 'interferon gamma' named entity 'zoonotic diseases' named entity 'alveolar septum' named entity 'neutrophils' named entity 'immune cell' named entity 'SARS' named entity 'Hyaline' named entity 'drug treatment' named entity 'MERS-CoV' named entity 'fever' named entity 'ATP' named entity 'embolic'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software